CryoPort (CYRX) vs Helus Pharma (HELP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Helus Pharma (HELP) has outperformed CryoPort (CYRX) over the past year, gaining 88.2% versus a gain of 74.5%. Over five years, CYRX leads with a -75.3% price change compared with -85.7% for HELP. CryoPort is the larger company by market cap ($878.8 million vs $862.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYRX | HELP |
|---|---|---|
| Share price | $17.35 | $11.80 |
| Market cap | $878.76M | $862.11M |
| 1-day change | +2.66% | +10.07% |
| YTD return | +80.73% | +44.25% |
| 1-year return | +74.55% | +88.20% |
| 5-year return | -75.31% | -85.68% |
| EPS (TTM) | $-0.81 | $-4.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.36 | $15.15 |
| 52-week low | $7.61 | $3.76 |
| Distance from 52-week high | -5.50% | -22.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +13.37% | +237.54% |
| Average volume | 641.47K | 1.77M |
| Shares outstanding | 50.65M | 73.06M |
| Employees | 684 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed CYRX by 13.7 percentage points over the past year.
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
CYRX vs HELP FAQ
Which is bigger, CryoPort or Helus Pharma?
CryoPort (CYRX) is larger, with a market capitalization of $878.76M compared with $862.11M for Helus Pharma (HELP).
Which stock has performed better over the past year, CYRX or HELP?
HELP returned +88.20% over the past 12 months, compared with +74.55% for CYRX (price return, excluding dividends). Past performance does not predict future results.
Are CryoPort and Helus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.